BioMarin rises after genetic disorder drug meets main goal in trial

BioMarin Pharmaceutical

21/05/2026 14:45

** Shares of drugmaker BioMarin Pharmaceutical BMRN.O climb 5.3% to $52.87

** Co said late on Wednesday its drug Voxzogo helped boost growth in patients with hypochondroplasia, a rare genetic condition, meeting the main goal of a late-stage study

** Hypochondroplasia affects bone growth and leads to short-limbed dwarfism

** The drug significantly increased the annualized growth rate with treated patients growing 2.33 cm more compared to those on placebo - BMRN

** "We believe that the positive late-stage data in hypochondroplasia should help BMRN to expand target population for Voxzogo to maintain the product's lead position in skeletal disorders" Wedbush says

** BMRN plans to submit a supplemental application to U.S. regulators in the third quarter of this year

** Including session's move, BMRN down 10.7% YTD

 (Reporting by Kunal Das in Bengaluru)

 ((Kunal.Das2@thomsonreuters.com;))